apararenone   Click here for help

GtoPdb Ligand ID: 12039

Synonyms: compound 39 [PMID: 35652647] | MT-3995 | MT3995
Compound class: Synthetic organic
Comment: Apararenone (MT-3995) is a selective and potent non-steroidal mineralocorticoid receptor (MR) antagonist [1]. It was developed to counteract MR-induced hypertension and organ damage in diseases including diabetic nephropathy and NASH.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 84.09
Molecular weight 364.09
XLogP 2.4
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1)N1c2ccc(cc2OC(C1=O)(C)C)NS(=O)(=O)C
Isomeric SMILES O=C1C(C)(C)Oc2cc(NS(=O)(=O)C)ccc2N1c1ccc(F)cc1
InChI InChI=1S/C17H17FN2O4S/c1-17(2)16(21)20(13-7-4-11(18)5-8-13)14-9-6-12(10-15(14)24-17)19-25(3,22)23/h4-10,19H,1-3H3
InChI Key AZNHWXAFPBYFGH-UHFFFAOYSA-N
References
1. Iijima T, Katoh M, Takedomi K, Yamamoto Y, Akatsuka H, Shirata N, Nishi A, Takakuwa M, Watanabe Y, Munakata H et al.. (2022)
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
J Med Chem, 65 (12): 8127-8143. [PMID:35652647]
2. Wada T, Inagaki M, Yoshinari T, Terata R, Totsuka N, Gotou M, Hashimoto G. (2021)
Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.
Clin Exp Nephrol, 25 (2): 120-130. [PMID:32974732]